Evidence‑Based Management of Type 2 Diabetes with Advanced Chronic Kidney Disease and High Cardiovascular Risk

Glycemic‑Control Strategy

Discontinue sulfonylureas (e.g., glibenclamide) in patients with advanced CKD because drug accumulation markedly increases the risk of severe hypoglycemia. 5
Prioritize avoidance of hypoglycemia over strict HbA1c targets when patients experience recurrent low‑glucose symptoms. 6
Initiate an SGLT2 inhibitor (empagliflozin or dapagliflozin) once estimated GFR is ≥20 mL/min/1.73 m² and continue it until dialysis, as it confers both cardiovascular and renal protection. 1
Continue metformin only when estimated GFR is ≥30 mL/min/1.73 m²; otherwise discontinue to prevent lactic‑acidosis risk. 2
Start a basal long‑acting insulin analog (e.g., insulin glargine U300 or degludec) to achieve glycemic control while minimizing hypoglycemia risk. 7
Aim for fasting glucose 100–150 mg/dL in older adults with multiple complications, balancing efficacy and safety. 6
Reduce insulin doses in CKD stage 4 because renal clearance of insulin is markedly decreased. 4
If the combination of SGLT2 inhibitor + basal insulin does not meet targets, add a GLP‑1 receptor agonist (liraglutide or semaglutide) for additional cardiovascular benefit and low hypoglycemia risk. 1
Set an individualized HbA1c goal of 7.5–8.0 % for patients ≥65 years with advanced complications; avoid targets < 7 % due to heightened hypoglycemia risk. 6

Target blood pressure <130/80 mmHg in adults with diabetes, CKD, and proteinuria. 9
Begin an ACE inhibitor or ARB as first‑line therapy for proteinuric CKD; these agents delay progression of diabetic nephropathy across all albuminuria stages. 5
Add a dihydropyridine calcium‑channel blocker (e.g., amlodipine) as a second agent when baseline BP ≥150/90 mmHg. 8
Introduce a thiazide‑type diuretic (chlorthalidone or indapamide) as a third‑line option if further BP reduction is needed. 8
Check serum potassium and creatinine 7–14 days after initiating or adjusting ACE‑I/ARB therapy, then after any subsequent dose change. 8
Recognize that hyper‑kalemia risk rises markedly when eGFR < 30 mL/min/1.73 m²; monitor potassium closely. 4
Avoid triple RAAS blockade (ACE‑I + ARB + mineralocorticoid antagonist) because of excessive hyper‑kalemia risk. 4

Prescribe high‑intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) for patients with very high cardiovascular risk due to diabetes, CKD stage 4, and probable coronary artery disease. 10
Aim for LDL‑C < 70 mg/dL in this high‑risk population. 10
All adults with diabetes and CKD should receive a statin regardless of baseline LDL‑C level. 3
If LDL‑C remains >70 mg/dL on maximally tolerated statin, add ezetimibe 10 mg daily. 10
Consider a PCSK9 inhibitor when LDL‑C is still above target despite statin + ezetimibe. 10

Add the non‑steroidal mineralocorticoid receptor antagonist finerenone after ACE‑I/ARB optimization and when serum potassium is within normal range; it reduces CKD progression and cardiovascular events in diabetes with albuminuria. 3
Monitor potassium closely whenever finerenone is combined with an ACE‑I or ARB. 3
Refer patients to nephrology promptly when eGFR falls below 30 mL/min/1.73 m² or when hypertension/hyper‑kalemia become difficult to manage. 5
Avoid NSAIDs because they increase hyper‑kalemia risk and accelerate kidney function decline. 4
Limit radiocontrast exposure; ensure adequate hydration if contrast studies are unavoidable. 5

Start low‑dose aspirin (75–100 mg daily) for secondary prevention after confirmed acute coronary syndrome; it may also be considered for primary prevention in patients with very high cardiovascular risk. 2
Screen for heart failure and initiate guideline‑directed therapy because diabetes and CKD markedly raise heart‑failure risk. 4
Add a beta‑blocker when coronary artery disease is confirmed to improve outcomes. 4

Self‑monitor blood glucose 3–4 times daily (fasting, pre‑meal, bedtime) for patients on insulin therapy. 9
Measure HbA1c every 3 months until target is reached, then every 6 months. 9
Consider continuous glucose monitoring to detect and prevent hypoglycemia. 6
Check serum creatinine, eGFR, and urine albumin‑to‑creatinine ratio every 3–6 months. 3
Re‑measure serum potassium 7–14 days after any medication change affecting the renin‑angiotensin‑aldosterone system or potassium balance. 8
Record blood pressure at every clinic visit; encourage home BP monitoring. 8
Obtain a lipid panel every 3–6 months until LDL‑C goal is achieved, then annually.

Limit dietary protein to ~0.8 g/kg body weight per day (≈10 % of total calories) in overt nephropathy. 5
Restrict sodium intake to <2,300 mg/day to aid blood‑pressure control and reduce proteinuria. 8
Avoid high‑potassium foods (e.g., bananas, oranges, tomatoes, potassium‑based salt substitutes) while on ACE‑I/ARB therapy. 4
Adopt a DASH‑style eating pattern rich in fruits, vegetables, and low‑fat dairy. 8
Engage in ≥150 minutes of moderate‑intensity aerobic activity each week, tailoring intensity to peripheral neuropathy and cardiovascular status. 8

Coordinate management among endocrinology, nephrology, cardiology, ophthalmology, and podiatry to address the multifaceted needs of patients with diabetes, CKD, and cardiovascular disease. 1
Utilize diabetes educators for medication administration training, glucose‑monitoring techniques, and sick‑day medication guidance. 2
Involve dietitians for individualized medical nutrition therapy targeting glycemic control, renal protection, and cardiovascular risk reduction. 1

Prioritize avoidance of hypoglycemia in elderly patients with cardiovascular disease and hypoglycemia unawareness. 6
Discontinue ACE‑I/ARB therapy if serum potassium exceeds 5.5 mmol/L despite corrective measures. 5
Counsel women of childbearing potential that ACE‑I and ARBs are contraindicated in pregnancy; ensure effective contraception. 8